Sanofi (SNY) Depreciation & Amortization (CF) (2009 - 2025)

Sanofi has reported Depreciation & Amortization (CF) for 17 years, with the latest figure at $367.1 million in Q1 2025.

• Quarterly Depreciation & Amortization (CF) rose 3.03% year-over-year to $367.1 million in Q1 2025, while the trailing twelve-month figure through Dec 2025 was $367.1 million (down 81.72% YoY) and the FY2024 annual result came in at $1.2 billion, down 3.51% from the prior year.
• Depreciation & Amortization (CF) fell to $367.1 million in Q1 2025 per SNY's latest filing, from $1.7 billion in the prior quarter.
• Over five years, Depreciation & Amortization (CF) peaked at $1.7 billion in Q4 2021 and troughed at $356.3 million in Q1 2024.
• A 5-year average of $946.6 million and a median of $418.6 million in 2021 frame the typical range for Depreciation & Amortization (CF).
• The sharpest annual moves came in 2021 and 2024: Depreciation & Amortization (CF) increased 3.31% in 2021, then fell 10.28% in 2024.
• Over 5 years, Depreciation & Amortization (CF) stood at $1.7 billion in 2021, then fell by 3.65% to $1.6 billion in 2022, then gained by 0.28% to $1.6 billion in 2023, then gained by 1.75% to $1.7 billion in 2024, then tumbled by 77.78% to $367.1 million in 2025.
• According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $367.1 million, $1.7 billion, and $356.3 million for Q1 2025, Q4 2024, and Q1 2024 respectively.